Additional loss of life expectancy and cost per life-year saved resulting from changes in colorectal cancer stage due to a 1-year diagnostic delay. by Hiroaki Saito (24514)

Conceptual diagram of survival curve and loss of life expectancy. by Hiroaki Saito (24514)

Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

Total bacterial count values at baseline and six months after treatment using systemic and local antibiotic treatment. by Iva Milinkovic (22331710)

The flow-diagram for the randomised clinical study. by Iva Milinkovic (22331710)

Difference in (a) IL-17, and (b) TNF-α relative gene expression levels between baseline and six months after treatment using systemic and local antibiotic treatment. by Iva Milinkovic (22331710)

Mean Values and Standard Deviations (Mean [±SD]) of Clinical Parameters: periodontal probing depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque ind... by Iva Milinkovic (22331710)

Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

“…Some <i>N</i>-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. …”

S8 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Study populations of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Future research directions. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

PRISMA flow diagram. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S9 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S7 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Participant characteristics of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Exercise protocols and results of included studies. by Martha R. Smith (20410184)

ROBINS-I assessments. by Martha R. Smith (20410184)

Participant characteristics in studies of children with biopsy-proven NAFLD. by Martha R. Smith (20410184)

RoB 2 assessments. by Martha R. Smith (20410184)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)